If you have pediatric patients with type 1 diabetes, consider prescribing NovoLog® as part of their care plan.
Effective for insulin use in children 2 years and older

NovoLog® is safe and effective in helping pediatric patients with type 1 diabetes reach age-specific A1C goals1
Studied in children aged 4 to 18 years. Age-specific A1C goals were defined as <8.5% for patients aged <6 years and <8% for patients aged 6 to 18 years, in alignment with the 2006 American Diabetes Association guidelines.
Percentage of patients who achieved their A1C goal1

P=0.040

Significantly lower daily dosing with NovoLog® at the end of the study1
NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.
Mean weight-adjusted
daily dose at Week 161

P=0.018

Safety results1
- Rates of minor, major, and nocturnal hypoglycemic events were similar with NovoLog® and insulin lispro
- The number of infusion site reactions also was similar, with 17% of NovoLog® patients and 21% of lispro patients reporting an infusion site reaction as an adverse event (P=0.43)
- Injection site reactions were defined to include catheter-site—related reaction, infusion site erythema, induration, irritation, pruritus, rash, reaction, swelling, and vesicles
Study design
A 16-week, open-label, multicenter, parallel-group study enrolling 298 patients with type 1 diabetes, aged 3 to 18 years. The efficacy and safety of NovoLog® continuous subcutaneous insulin infusion (CSII) therapy were compared with those of insulin lispro. Although patients as young as 3 years were eligible for inclusion, the youngest child included in the study was aged 4 years. The primary endpoint was change in A1C from baseline to the end of the study.1
